Biotech Vivus (VVUS) popped nearly 13% early Wednesday after insurer Aetna (AET) revised its weight-loss-treatment policy to include Vivus' obesity drug Qsymia. In a revision issued Tuesday to its clinical policy, Aetna outlined the conditions to be met for obesity-treatment coverage and listed the approved treatments, now including Qsymia and Arena Pharmaceuticals (ARNA) Belviq, both of which have been cleared by the FDA since the last review of